bullous pemphigoid
Conditions
Interventions
Control Group (C):apply 0.05% halometasone cream daily
Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids
Sponsors
Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically Diagnosed bullous pemphigoid patients; 2. No age or gender limitation; 3. Participant or legal guardian fully understands the content of the clinical trial, is willing to attend the research voluntary andsign the informed consent form; 4. Physical examination is qualified, participant does not have previous severe systemic disease.
Exclusion criteria
Exclusion criteria: 1. physical examination failed to qualify for enrollment; 2. during gestational andlactation period; 3. known allergic history toward drug or moisturizer under study; 4. severe psoriasis vulgaris patients; 5. involved in any other clinical trial three months before enrollment; 6. frequently usage of herbal, hypnotics, sedative, stabilizers, or other addictive medication; 7. alcoholics, psychotic, or participants who cannot follow prescription order; 8. heart, respiratory failure, severe diseases; 9. skin disease that may interfere with evaluation of psoriasis, or life-threatening skin disease, history of severe skin disease other than psoriasis; 10. systemic therapy of GC within 2 weeks of screening; 11. topical therapy of group I GC within2 weeks of screening; 12. any systemic therapy for psoriasis (including herbal, chinese medicine) within 4 weeks of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| daily new blister;duration of disease control;recurrent rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythema area;Pruritus;age;gender;percentage of peripheral blood eosinophils;Immunoglobulin E;anti-BP180 IgG;anti-BP180 IgE;anti-BP230 IgG;anti-BP230 IgE; | — |
Countries
China
Contacts
Public ContactPAN MENG
Outcome results
None listed